Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67

Table 3 Correlation between clinicopathological features and Ki67, E-cadherin, and p53 expression in 190 triple-negative breast cancers

	Ki67		P-value	E-cadherin		P-value	Ki67 (+) and E-cadherin (-)		P-value	p53		P-value
Parameters	Positive	Negative		Positive	Negative		Positive	Negative		Positive	Negative
	( n = 109)	( n = 81)		( n = 65)	( n = 125)		( n = 68)	( n = 122)		( n = 118)	( n = 72)
Age at operation
≤ 55	49 (58%)	35 (42%)		29 (35%)	55 (65%)		31 (37%)	53 (63%)		57 (68%)	27 (32%)
> 55	60 (57%)	46 (43%)	0.811	36 (34%)	70 (66%)	0.935	37 (35%)	69 (65%)	0.775	61 (57%)	45 (43%)	0.146
Pathological stage
I	26 (44%)	33 (56%)		20 (34%)	39 (66%)		16 (27%)	43 (73%)		36 (61%)	23 (39%)
II and III	83 (63%)	48 (37%)	0.013	45 (34%)	86 (66%)	0.951	52 (40%)	79 (60%)	0.094	82 (63%)	49 (37%)	0.836
pTumor size
≤ 2 cm	37 (49%)	38 (51%)		24 (32%)	51 (68%)		26 (35%)	49 (65%)		45 (60%)	30 (40%)
> 2 cm	72 (63%)	43 (37%)	0.071	41 (36%)	74 (64%)	0.604	42 (37%)	73 (63%)	0.794	73 (63%)	42 (37%)	0.629
pLymph node status
Negative	60 (52%)	55 (48%)		43 (37%)	72 (63%)		34 (30%)	81 (70%)		70 (61%)	45 (39%)
Positive	49 (65%)	26 (35%)	0.073	22 (31%)	53 (69%)	0.252	34 (45%)	41 (55%)	0.027	48 (64%)	27 (36%)	0.664
Lymph-vascular invasion
Negative	72 (54%)	60 (46%)		49 (37%)	83 (63%)		43 (33%)	89 (67%)		79 (60%)	53 (40%)
Positive	37 (64%)	21 (36%)	0.235	16 (28%)	42 (72%)	0.202	25 (43%)	33 (57%)	0.163	39 (67%)	19 (33%)	0.333
Histologic type
Invasive ductal carcinoma	96 (58%)	68 (42%)		60 (37%)	104 (63%)		58 (35%)	106 (65%)		102 (62%)	62 (38%)
Special type	13 (50%)	13 (50%)	0.414	5 (19%)	21 (81%)	0.083	10 (38%)	16 (62%)	0.76	16 (61%)	10 (39%)	0.949
Nuclear grade	46 (42%)	37 (46%)		33 (51%)	50 (40%)		27 (40%)	56 (46%)		45(38%)	38 (53%)
1,& 2,	63 (58%)	44 (54%)		32 (49%)	75 (60%)		41 (60%)	66 (54%)		73 (62%)	34 (47%)
3			0.633			0.156			0.409			0.048

ISSN: 1465-542X